Page 3 - Shin Ashida News Today : Breaking News, Live Updates & Top Stories | Vimarsana

JCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo® Technology

JCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo® Technology
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesShin ashidaPharmaceuticals co ltdCorporate communicationsPlatform technologyResearch collaborationLicense agreementAstrazeneca rare diseaseJ brain cargoBrain cargo

U S FDA Grants Orphan Drug Designation to JR-441 for the Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)

JCR Pharmaceuticals Co., Ltd. announced that the U.S. Food and Drug Administration granted orphan drug designation to JR-441, an investigational drug for the treatment of mucopolysaccharidosis.

United statesShin ashidaOffice of orphan products developmentDrug administrationEuropean commissionPharmaceuticals co ltdOrphan drug designationDrug designationOrphan products developmentPrescription drug user fee act applicationSanfilippo syndrome

JCR Pharmaceuticals Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA

JCR Pharmaceuticals Co., Ltd. announced today that the first patient in the Phase I/II clinical trial with Mucopolysaccharidosis Type IIIA has been dosed with JR‑441, a blood-brain barrier .

Nordrhein westfalenUnited statesNicole muscholShin ashidaPharmaceuticals co ltdUniversity hospital of hamburg eppendorfInternational centerEuropean commissionMucopolysaccharidosis typeSanfilippo syndrome typeLysosomal disordersUniversity hospitalHamburg eppendorfPrincipal investigator

JCR Pharmaceuticals Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)

JCR Pharmaceuticals Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPaul harmatzShin ashidaPlatform technologyCorporate communicationsPharmaceuticals co ltdDrug administrationHost webinarPresent further detailsJ brain cargoFast track

JCR Pharmaceuticals : FY2022 Second-Half Results Briefing Session -Script-（6,169KB）

JCR Pharmaceuticals Co., Ltd. Financial Results Briefing for the Fiscal Year Ended March 2023 May 12, 2023 . | May 16, 2023

United statesShinya tsuzukiYoh itoHidemaru yamaguchiToru ashidaHiroyuki matsubaraRyuta kawamuraNaomi kumagaiMathias schmidtYoshihiro ohtaKazuaki hashiguchiMorgan stanleyShin ashidaYutaka hondaHiroyuki sonodaShinichiro muraoka